Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 125 | 2024 | 2881 | 15.770 |
Why?
|
Genetic Predisposition to Disease | 54 | 2024 | 2267 | 4.090 |
Why?
|
Female | 221 | 2024 | 44405 | 2.760 |
Why?
|
Genes, BRCA1 | 13 | 2019 | 192 | 2.380 |
Why?
|
Estrogen Receptor alpha | 8 | 2017 | 144 | 2.340 |
Why?
|
Genome-Wide Association Study | 25 | 2023 | 1611 | 2.320 |
Why?
|
Diethylstilbestrol | 9 | 2021 | 119 | 2.280 |
Why?
|
Prenatal Exposure Delayed Effects | 9 | 2021 | 153 | 2.260 |
Why?
|
Biomarkers, Tumor | 19 | 2021 | 1461 | 2.190 |
Why?
|
Middle Aged | 142 | 2023 | 24957 | 2.160 |
Why?
|
Germ-Line Mutation | 14 | 2021 | 329 | 2.160 |
Why?
|
Mastectomy | 6 | 2023 | 234 | 2.130 |
Why?
|
Polymorphism, Single Nucleotide | 41 | 2024 | 2350 | 2.120 |
Why?
|
Humans | 255 | 2024 | 86281 | 2.070 |
Why?
|
Prognosis | 34 | 2023 | 3669 | 1.940 |
Why?
|
Triple Negative Breast Neoplasms | 8 | 2023 | 136 | 1.870 |
Why?
|
Genes, BRCA2 | 8 | 2019 | 160 | 1.850 |
Why?
|
Receptors, Progesterone | 8 | 2017 | 165 | 1.820 |
Why?
|
Adult | 125 | 2023 | 25577 | 1.810 |
Why?
|
Case-Control Studies | 36 | 2023 | 1801 | 1.720 |
Why?
|
Aged | 88 | 2023 | 18353 | 1.660 |
Why?
|
Substance Abuse, Intravenous | 9 | 2009 | 54 | 1.620 |
Why?
|
Neoplasms, Second Primary | 7 | 2014 | 252 | 1.570 |
Why?
|
Risk Factors | 49 | 2024 | 5397 | 1.500 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2023 | 1305 | 1.490 |
Why?
|
Needle-Exchange Programs | 7 | 2009 | 18 | 1.390 |
Why?
|
Nigeria | 29 | 2023 | 152 | 1.390 |
Why?
|
Breast Neoplasms, Male | 5 | 2017 | 30 | 1.390 |
Why?
|
Neoplasm Staging | 19 | 2023 | 1932 | 1.340 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2021 | 291 | 1.340 |
Why?
|
Receptors, Estrogen | 13 | 2022 | 382 | 1.320 |
Why?
|
BRCA1 Protein | 14 | 2019 | 199 | 1.290 |
Why?
|
Adenocarcinoma, Clear Cell | 3 | 2018 | 62 | 1.250 |
Why?
|
Vaginal Neoplasms | 2 | 2018 | 83 | 1.240 |
Why?
|
Mutation | 23 | 2023 | 3952 | 1.200 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2015 | 156 | 1.180 |
Why?
|
Carcinoma, Lobular | 4 | 2015 | 80 | 1.180 |
Why?
|
Genetic Loci | 8 | 2019 | 250 | 1.180 |
Why?
|
Receptor, ErbB-2 | 11 | 2023 | 223 | 1.150 |
Why?
|
Cohort Studies | 26 | 2023 | 2759 | 1.150 |
Why?
|
Urology | 7 | 2020 | 108 | 1.130 |
Why?
|
Aged, 80 and over | 41 | 2021 | 6481 | 1.120 |
Why?
|
Databases, Factual | 11 | 2021 | 808 | 1.100 |
Why?
|
Body Mass Index | 11 | 2021 | 770 | 1.070 |
Why?
|
BRCA2 Protein | 10 | 2019 | 157 | 1.060 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2018 | 274 | 1.020 |
Why?
|
United States | 25 | 2021 | 6637 | 1.010 |
Why?
|
Practice Patterns, Physicians' | 2 | 2021 | 578 | 1.000 |
Why?
|
Risk-Taking | 7 | 2009 | 148 | 0.960 |
Why?
|
Genetic Testing | 8 | 2023 | 535 | 0.960 |
Why?
|
Logistic Models | 16 | 2017 | 1184 | 0.950 |
Why?
|
Complementary Therapies | 2 | 2023 | 54 | 0.930 |
Why?
|
Biomedical Research | 7 | 2020 | 375 | 0.920 |
Why?
|
Needle Sharing | 6 | 2007 | 14 | 0.910 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 315 | 0.910 |
Why?
|
Yoga | 1 | 2023 | 5 | 0.910 |
Why?
|
Meditation | 1 | 2023 | 5 | 0.910 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 857 | 0.910 |
Why?
|
Healthcare Disparities | 4 | 2023 | 369 | 0.910 |
Why?
|
Body Weight | 3 | 2021 | 459 | 0.900 |
Why?
|
Ovarian Neoplasms | 9 | 2019 | 738 | 0.880 |
Why?
|
Metabolome | 1 | 2023 | 47 | 0.880 |
Why?
|
Carcinoma | 4 | 2015 | 434 | 0.870 |
Why?
|
Guideline Adherence | 4 | 2019 | 222 | 0.850 |
Why?
|
Survival Analysis | 17 | 2021 | 1536 | 0.850 |
Why?
|
Glucuronosyltransferase | 7 | 2014 | 184 | 0.840 |
Why?
|
Neoplasms | 9 | 2023 | 2889 | 0.830 |
Why?
|
Menarche | 1 | 2021 | 24 | 0.830 |
Why?
|
Antineoplastic Agents | 8 | 2018 | 2351 | 0.820 |
Why?
|
Quantitative Trait Loci | 2 | 2023 | 576 | 0.780 |
Why?
|
Telemedicine | 1 | 2023 | 168 | 0.770 |
Why?
|
Standard of Care | 1 | 2021 | 78 | 0.770 |
Why?
|
Withholding Treatment | 1 | 2021 | 111 | 0.760 |
Why?
|
Breast | 8 | 2023 | 286 | 0.750 |
Why?
|
Retrospective Studies | 24 | 2023 | 8431 | 0.740 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 64 | 0.730 |
Why?
|
Radiation Injuries | 1 | 2021 | 155 | 0.730 |
Why?
|
Lung Neoplasms | 4 | 2023 | 2260 | 0.730 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2020 | 114 | 0.730 |
Why?
|
Age Factors | 16 | 2023 | 1842 | 0.720 |
Why?
|
Women's Health | 3 | 2021 | 100 | 0.720 |
Why?
|
Follow-Up Studies | 18 | 2020 | 3616 | 0.720 |
Why?
|
Young Adult | 20 | 2020 | 5961 | 0.680 |
Why?
|
Pancreatic Neoplasms | 4 | 2020 | 645 | 0.680 |
Why?
|
Pandemics | 2 | 2023 | 739 | 0.670 |
Why?
|
Male | 95 | 2023 | 40860 | 0.670 |
Why?
|
Transcriptome | 1 | 2023 | 574 | 0.670 |
Why?
|
Program Evaluation | 5 | 2011 | 297 | 0.670 |
Why?
|
MicroRNAs | 4 | 2016 | 534 | 0.660 |
Why?
|
Incidence | 14 | 2021 | 1568 | 0.650 |
Why?
|
Haptoglobins | 1 | 2017 | 9 | 0.630 |
Why?
|
Early Detection of Cancer | 7 | 2018 | 387 | 0.620 |
Why?
|
Patient Acceptance of Health Care | 2 | 2017 | 237 | 0.620 |
Why?
|
Body Height | 4 | 2021 | 99 | 0.620 |
Why?
|
Prostatic Neoplasms | 12 | 2020 | 1708 | 0.620 |
Why?
|
Parity | 4 | 2015 | 93 | 0.620 |
Why?
|
Adolescent | 27 | 2020 | 8968 | 0.610 |
Why?
|
Bayes Theorem | 2 | 2016 | 360 | 0.610 |
Why?
|
Bone Neoplasms | 3 | 2017 | 322 | 0.590 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2016 | 54 | 0.590 |
Why?
|
Circulating MicroRNA | 1 | 2016 | 12 | 0.580 |
Why?
|
Ribonuclease III | 1 | 2016 | 14 | 0.580 |
Why?
|
Neoplasm Metastasis | 9 | 2016 | 1056 | 0.570 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 150 | 0.570 |
Why?
|
Adenocarcinoma | 9 | 2018 | 1160 | 0.560 |
Why?
|
Brachytherapy | 2 | 2014 | 119 | 0.560 |
Why?
|
Mendelian Randomization Analysis | 4 | 2019 | 43 | 0.560 |
Why?
|
Genomics | 2 | 2020 | 710 | 0.560 |
Why?
|
Neoplasm Grading | 5 | 2021 | 356 | 0.560 |
Why?
|
Genome, Human | 2 | 2020 | 756 | 0.560 |
Why?
|
Biological Products | 1 | 2018 | 143 | 0.560 |
Why?
|
Pregnancy | 14 | 2021 | 2885 | 0.550 |
Why?
|
Gene Expression Regulation, Neoplastic | 11 | 2017 | 1196 | 0.540 |
Why?
|
Lymph Node Excision | 3 | 2017 | 211 | 0.540 |
Why?
|
Guidelines as Topic | 4 | 2020 | 162 | 0.540 |
Why?
|
Genotype | 17 | 2023 | 1850 | 0.530 |
Why?
|
Odds Ratio | 8 | 2013 | 677 | 0.520 |
Why?
|
Risk Assessment | 16 | 2024 | 2253 | 0.520 |
Why?
|
Research Design | 7 | 2020 | 594 | 0.520 |
Why?
|
Nuclear Proteins | 2 | 2017 | 694 | 0.520 |
Why?
|
Quality of Life | 5 | 2021 | 1575 | 0.510 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2014 | 100 | 0.510 |
Why?
|
Mass Screening | 6 | 2018 | 615 | 0.500 |
Why?
|
Tumor Suppressor Protein p53 | 6 | 2022 | 380 | 0.500 |
Why?
|
Survival Rate | 11 | 2023 | 1856 | 0.490 |
Why?
|
DNA-Binding Proteins | 4 | 2016 | 1208 | 0.490 |
Why?
|
Chicago | 12 | 2021 | 1377 | 0.490 |
Why?
|
Cross-Sectional Studies | 11 | 2023 | 1610 | 0.480 |
Why?
|
Quality of Health Care | 1 | 2017 | 380 | 0.480 |
Why?
|
Estrogen Replacement Therapy | 1 | 2013 | 45 | 0.470 |
Why?
|
Demography | 3 | 2023 | 177 | 0.470 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 28 | 0.470 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 111 | 0.460 |
Why?
|
Breast Feeding | 3 | 2012 | 91 | 0.460 |
Why?
|
Colonic Neoplasms | 3 | 2018 | 554 | 0.450 |
Why?
|
Periodicals as Topic | 3 | 2020 | 167 | 0.450 |
Why?
|
Population Surveillance | 3 | 2019 | 219 | 0.440 |
Why?
|
Neoplasm Proteins | 4 | 2012 | 532 | 0.440 |
Why?
|
Lymphatic Metastasis | 4 | 2018 | 480 | 0.430 |
Why?
|
HIV Infections | 6 | 2009 | 768 | 0.430 |
Why?
|
Longitudinal Studies | 7 | 2023 | 1015 | 0.430 |
Why?
|
Prostate-Specific Antigen | 5 | 2020 | 346 | 0.430 |
Why?
|
Sexual Behavior | 2 | 2020 | 301 | 0.430 |
Why?
|
Developed Countries | 1 | 2012 | 24 | 0.420 |
Why?
|
Motor Activity | 1 | 2014 | 327 | 0.420 |
Why?
|
Brain Neoplasms | 1 | 2017 | 763 | 0.420 |
Why?
|
Alleles | 9 | 2019 | 1127 | 0.410 |
Why?
|
Urban Population | 5 | 2019 | 213 | 0.410 |
Why?
|
Developing Countries | 1 | 2012 | 69 | 0.410 |
Why?
|
Genetic Association Studies | 8 | 2019 | 294 | 0.410 |
Why?
|
Telomerase | 1 | 2011 | 55 | 0.410 |
Why?
|
Prospective Studies | 14 | 2024 | 4194 | 0.400 |
Why?
|
Liver Neoplasms | 1 | 2017 | 731 | 0.400 |
Why?
|
Kaplan-Meier Estimate | 6 | 2023 | 859 | 0.400 |
Why?
|
Lymph Nodes | 1 | 2015 | 530 | 0.400 |
Why?
|
Registries | 5 | 2021 | 702 | 0.400 |
Why?
|
Health Status | 3 | 2014 | 360 | 0.400 |
Why?
|
Colitis, Ulcerative | 7 | 2018 | 708 | 0.400 |
Why?
|
Respiratory Distress Syndrome, Newborn | 5 | 2010 | 53 | 0.390 |
Why?
|
Health Surveys | 5 | 2021 | 238 | 0.390 |
Why?
|
Air Pollution, Indoor | 3 | 2017 | 61 | 0.380 |
Why?
|
Diabetes Complications | 1 | 2012 | 206 | 0.370 |
Why?
|
Time Factors | 10 | 2021 | 5198 | 0.370 |
Why?
|
Health Status Disparities | 2 | 2023 | 170 | 0.370 |
Why?
|
Risk | 9 | 2021 | 673 | 0.370 |
Why?
|
Multivariate Analysis | 8 | 2017 | 997 | 0.360 |
Why?
|
Genes, erbB-2 | 1 | 2009 | 24 | 0.360 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2023 | 468 | 0.360 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2020 | 1372 | 0.360 |
Why?
|
Africa | 4 | 2021 | 98 | 0.360 |
Why?
|
Estrogens, Non-Steroidal | 2 | 2020 | 30 | 0.350 |
Why?
|
Colorectal Neoplasms | 6 | 2015 | 924 | 0.350 |
Why?
|
Mammography | 4 | 2018 | 460 | 0.350 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 302 | 0.340 |
Why?
|
Mastectomy, Segmental | 2 | 2021 | 91 | 0.340 |
Why?
|
Prevalence | 8 | 2021 | 1239 | 0.340 |
Why?
|
Endocrine Disruptors | 2 | 2019 | 27 | 0.340 |
Why?
|
Biostatistics | 2 | 2019 | 20 | 0.340 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2009 | 109 | 0.340 |
Why?
|
SEER Program | 4 | 2014 | 181 | 0.330 |
Why?
|
Myelodysplastic Syndromes | 4 | 2007 | 345 | 0.330 |
Why?
|
Maternal Exposure | 2 | 2019 | 57 | 0.330 |
Why?
|
Gene Frequency | 7 | 2016 | 676 | 0.330 |
Why?
|
Rectal Neoplasms | 1 | 2009 | 114 | 0.320 |
Why?
|
Combined Modality Therapy | 7 | 2023 | 1680 | 0.320 |
Why?
|
Reinforcement, Verbal | 1 | 2007 | 5 | 0.310 |
Why?
|
Mental Recall | 2 | 2015 | 158 | 0.300 |
Why?
|
Radiotherapy | 1 | 2009 | 326 | 0.300 |
Why?
|
Chromosome Aberrations | 5 | 2012 | 386 | 0.300 |
Why?
|
Genetic Variation | 5 | 2019 | 1349 | 0.300 |
Why?
|
Chromosomes, Human, Pair 6 | 3 | 2019 | 125 | 0.300 |
Why?
|
Medical Records | 1 | 2007 | 119 | 0.290 |
Why?
|
Crohn Disease | 2 | 2018 | 729 | 0.290 |
Why?
|
Disclosure | 1 | 2007 | 108 | 0.290 |
Why?
|
Interleukin-11 | 3 | 2016 | 20 | 0.290 |
Why?
|
Cooking | 3 | 2017 | 53 | 0.280 |
Why?
|
Introns | 3 | 2021 | 289 | 0.280 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2007 | 152 | 0.280 |
Why?
|
Computer Graphics | 3 | 2020 | 100 | 0.270 |
Why?
|
Age Distribution | 3 | 2013 | 204 | 0.270 |
Why?
|
Life Expectancy | 3 | 2015 | 85 | 0.270 |
Why?
|
Statistics as Topic | 3 | 2020 | 237 | 0.270 |
Why?
|
Immunologic Factors | 1 | 2007 | 170 | 0.270 |
Why?
|
Rural Population | 5 | 2019 | 136 | 0.270 |
Why?
|
Editorial Policies | 3 | 2020 | 32 | 0.260 |
Why?
|
Gastrointestinal Agents | 1 | 2007 | 161 | 0.260 |
Why?
|
Postmenopause | 3 | 2013 | 98 | 0.260 |
Why?
|
Membrane Proteins | 1 | 2011 | 1194 | 0.260 |
Why?
|
Smoke | 2 | 2016 | 27 | 0.260 |
Why?
|
Data Interpretation, Statistical | 3 | 2020 | 297 | 0.260 |
Why?
|
Heterozygote | 4 | 2019 | 365 | 0.250 |
Why?
|
Immunohistochemistry | 7 | 2023 | 1752 | 0.250 |
Why?
|
Subarachnoid Hemorrhage | 4 | 2007 | 136 | 0.250 |
Why?
|
Anti-Inflammatory Agents | 1 | 2007 | 339 | 0.250 |
Why?
|
Child | 14 | 2018 | 6913 | 0.240 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2008 | 755 | 0.240 |
Why?
|
DNA Mutational Analysis | 8 | 2021 | 526 | 0.240 |
Why?
|
Reproductive History | 1 | 2003 | 8 | 0.240 |
Why?
|
Leukemia, Myeloid | 4 | 2012 | 249 | 0.240 |
Why?
|
Biopsy | 7 | 2021 | 1160 | 0.240 |
Why?
|
Signal Transduction | 6 | 2018 | 3233 | 0.230 |
Why?
|
Microfilament Proteins | 3 | 2016 | 206 | 0.230 |
Why?
|
Linear Models | 4 | 2015 | 419 | 0.230 |
Why?
|
Asthma | 3 | 2017 | 947 | 0.230 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2016 | 302 | 0.230 |
Why?
|
Premature Birth | 2 | 2018 | 112 | 0.230 |
Why?
|
Genetic Services | 1 | 2023 | 7 | 0.230 |
Why?
|
Personal Satisfaction | 1 | 2023 | 62 | 0.230 |
Why?
|
Haplotypes | 6 | 2011 | 642 | 0.230 |
Why?
|
Jews | 2 | 2016 | 42 | 0.230 |
Why?
|
Hip Fractures | 1 | 2003 | 45 | 0.230 |
Why?
|
Linkage Disequilibrium | 4 | 2013 | 473 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2012 | 2434 | 0.220 |
Why?
|
Diphosphonates | 3 | 2007 | 36 | 0.220 |
Why?
|
Body Weights and Measures | 2 | 2021 | 27 | 0.220 |
Why?
|
Cell Line, Tumor | 12 | 2016 | 2421 | 0.220 |
Why?
|
Metabolomics | 1 | 2023 | 67 | 0.220 |
Why?
|
Environmental Exposure | 2 | 2017 | 296 | 0.220 |
Why?
|
Bone Density Conservation Agents | 3 | 2007 | 45 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2015 | 120 | 0.220 |
Why?
|
Promoter Regions, Genetic | 5 | 2016 | 937 | 0.220 |
Why?
|
Hormones | 1 | 2023 | 140 | 0.210 |
Why?
|
Premenopause | 2 | 2013 | 54 | 0.210 |
Why?
|
Database Management Systems | 1 | 2002 | 41 | 0.210 |
Why?
|
Patient Satisfaction | 3 | 2023 | 452 | 0.210 |
Why?
|
Imidazoles | 3 | 2007 | 163 | 0.210 |
Why?
|
Clonal Evolution | 1 | 2021 | 15 | 0.210 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2015 | 74 | 0.210 |
Why?
|
Physician-Patient Relations | 1 | 2007 | 610 | 0.210 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2023 | 25 | 0.200 |
Why?
|
Antibodies, Monoclonal | 2 | 2007 | 1376 | 0.200 |
Why?
|
Birth Weight | 3 | 2019 | 144 | 0.200 |
Why?
|
Comorbidity | 3 | 2021 | 943 | 0.200 |
Why?
|
MAP Kinase Kinase 4 | 3 | 2008 | 67 | 0.200 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2021 | 1200 | 0.200 |
Why?
|
Maternal-Fetal Exchange | 2 | 2018 | 76 | 0.200 |
Why?
|
Nitric Oxide | 3 | 2010 | 277 | 0.200 |
Why?
|
Up-Regulation | 3 | 2016 | 710 | 0.200 |
Why?
|
Obesity | 4 | 2013 | 962 | 0.200 |
Why?
|
Neoplasms, Basal Cell | 2 | 2011 | 9 | 0.200 |
Why?
|
Datasets as Topic | 2 | 2019 | 71 | 0.200 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2018 | 56 | 0.200 |
Why?
|
Sequence Analysis, DNA | 4 | 2011 | 853 | 0.200 |
Why?
|
beta Catenin | 2 | 2015 | 250 | 0.200 |
Why?
|
Social Isolation | 1 | 2021 | 67 | 0.200 |
Why?
|
Uganda | 4 | 2023 | 34 | 0.190 |
Why?
|
Specimen Handling | 1 | 2021 | 98 | 0.190 |
Why?
|
Gallbladder Diseases | 1 | 2020 | 22 | 0.190 |
Why?
|
Genotyping Techniques | 2 | 2020 | 68 | 0.190 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 551 | 0.190 |
Why?
|
Gene Expression Profiling | 6 | 2021 | 1381 | 0.190 |
Why?
|
Sequence Deletion | 2 | 2019 | 205 | 0.190 |
Why?
|
Genes, Tumor Suppressor | 2 | 2016 | 157 | 0.190 |
Why?
|
Trans-Activators | 3 | 2021 | 429 | 0.190 |
Why?
|
Health Expenditures | 1 | 2021 | 86 | 0.190 |
Why?
|
Medicine, African Traditional | 1 | 2020 | 3 | 0.190 |
Why?
|
Esophageal Neoplasms | 1 | 2023 | 320 | 0.190 |
Why?
|
Treatment Outcome | 18 | 2019 | 7949 | 0.190 |
Why?
|
Health Services Accessibility | 2 | 2021 | 392 | 0.190 |
Why?
|
Patient Reported Outcome Measures | 1 | 2021 | 165 | 0.190 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 1671 | 0.180 |
Why?
|
United Kingdom | 1 | 2020 | 164 | 0.180 |
Why?
|
Soybean Proteins | 1 | 2019 | 5 | 0.180 |
Why?
|
Soy Foods | 1 | 2019 | 3 | 0.180 |
Why?
|
Multifactorial Inheritance | 2 | 2022 | 158 | 0.180 |
Why?
|
Capecitabine | 1 | 2020 | 95 | 0.180 |
Why?
|
Health Personnel | 1 | 2022 | 202 | 0.180 |
Why?
|
Fanconi Anemia Complementation Group C Protein | 1 | 2019 | 4 | 0.180 |
Why?
|
Propensity Score | 1 | 2020 | 136 | 0.180 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2020 | 236 | 0.180 |
Why?
|
Gender Identity | 1 | 2020 | 52 | 0.180 |
Why?
|
Electronic Health Records | 1 | 2023 | 319 | 0.180 |
Why?
|
Polymorphism, Genetic | 3 | 2008 | 819 | 0.180 |
Why?
|
Radiotherapy Dosage | 4 | 2014 | 468 | 0.180 |
Why?
|
Socioeconomic Factors | 7 | 2020 | 567 | 0.170 |
Why?
|
Publishing | 1 | 2020 | 90 | 0.170 |
Why?
|
Models, Statistical | 3 | 2021 | 574 | 0.170 |
Why?
|
Menstruation Disturbances | 1 | 2018 | 24 | 0.170 |
Why?
|
DNA Repair | 3 | 2011 | 356 | 0.170 |
Why?
|
DNA Methylation | 2 | 2016 | 622 | 0.170 |
Why?
|
Severity of Illness Index | 3 | 2021 | 1796 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 2 | 2009 | 30 | 0.170 |
Why?
|
Homologous Recombination | 1 | 2018 | 51 | 0.160 |
Why?
|
Breast Diseases | 1 | 2018 | 97 | 0.160 |
Why?
|
Developmental Disabilities | 3 | 2010 | 194 | 0.160 |
Why?
|
Surveys and Questionnaires | 6 | 2020 | 2495 | 0.160 |
Why?
|
Internationality | 1 | 2018 | 69 | 0.160 |
Why?
|
Precision Medicine | 2 | 2023 | 394 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2006 | 1075 | 0.160 |
Why?
|
Medicare | 1 | 2021 | 404 | 0.160 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 199 | 0.160 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 9 | 0.160 |
Why?
|
Child Development | 2 | 2009 | 163 | 0.160 |
Why?
|
Practice Guidelines as Topic | 2 | 2017 | 1030 | 0.160 |
Why?
|
Age of Onset | 5 | 2018 | 306 | 0.150 |
Why?
|
ras Proteins | 2 | 2011 | 128 | 0.150 |
Why?
|
Chromosome Mapping | 3 | 2019 | 1074 | 0.150 |
Why?
|
Carcinogens | 1 | 2017 | 108 | 0.150 |
Why?
|
Bone Density | 3 | 2007 | 209 | 0.150 |
Why?
|
Genomic Instability | 2 | 2021 | 79 | 0.150 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2017 | 64 | 0.150 |
Why?
|
Harm Reduction | 2 | 2007 | 15 | 0.150 |
Why?
|
Depression | 2 | 2019 | 472 | 0.150 |
Why?
|
Confidence Intervals | 3 | 2013 | 228 | 0.150 |
Why?
|
Base Sequence | 5 | 2012 | 2329 | 0.150 |
Why?
|
Gene-Environment Interaction | 1 | 2018 | 103 | 0.150 |
Why?
|
Postpartum Period | 2 | 2018 | 135 | 0.150 |
Why?
|
Lumbar Vertebrae | 2 | 2008 | 148 | 0.150 |
Why?
|
Travel | 1 | 2017 | 68 | 0.150 |
Why?
|
China | 3 | 2021 | 228 | 0.150 |
Why?
|
Colonic Polyps | 1 | 2018 | 126 | 0.150 |
Why?
|
Africa South of the Sahara | 3 | 2023 | 21 | 0.140 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 2007 | 103 | 0.140 |
Why?
|
Toll-Like Receptor 3 | 1 | 2016 | 9 | 0.140 |
Why?
|
Homeodomain Proteins | 1 | 2020 | 535 | 0.140 |
Why?
|
Hepacivirus | 2 | 2016 | 159 | 0.140 |
Why?
|
Pedigree | 2 | 2016 | 966 | 0.140 |
Why?
|
Chemoprevention | 2 | 2014 | 91 | 0.140 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2017 | 182 | 0.140 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.140 |
Why?
|
Minority Groups | 2 | 2009 | 132 | 0.140 |
Why?
|
Drug Prescriptions | 1 | 2017 | 141 | 0.140 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2017 | 108 | 0.140 |
Why?
|
Minimally Invasive Surgical Procedures | 2 | 2008 | 234 | 0.140 |
Why?
|
Cameroon | 3 | 2023 | 14 | 0.140 |
Why?
|
Carcinoma, Papillary | 1 | 2017 | 158 | 0.140 |
Why?
|
Postoperative Care | 1 | 2017 | 220 | 0.140 |
Why?
|
Tumor Burden | 1 | 2017 | 288 | 0.140 |
Why?
|
Lymphoma, T-Cell | 2 | 2007 | 48 | 0.130 |
Why?
|
Treatment Failure | 1 | 2016 | 284 | 0.130 |
Why?
|
Double-Blind Method | 7 | 2010 | 1822 | 0.130 |
Why?
|
Pregnancy Complications | 1 | 2018 | 336 | 0.130 |
Why?
|
Directly Observed Therapy | 1 | 2015 | 5 | 0.130 |
Why?
|
Hepatocytes | 1 | 2016 | 127 | 0.130 |
Why?
|
Mesothelioma | 1 | 2018 | 309 | 0.130 |
Why?
|
Vitamin D | 1 | 2017 | 261 | 0.130 |
Why?
|
Drug Users | 1 | 2015 | 18 | 0.130 |
Why?
|
Heat-Shock Proteins | 1 | 2016 | 178 | 0.130 |
Why?
|
Antitubercular Agents | 1 | 2015 | 52 | 0.130 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 1987 | 0.130 |
Why?
|
Proto-Oncogene Proteins | 2 | 2011 | 645 | 0.130 |
Why?
|
Deoxycytidine | 3 | 2006 | 237 | 0.130 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2017 | 689 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2007 | 101 | 0.130 |
Why?
|
Microsatellite Repeats | 2 | 2012 | 141 | 0.130 |
Why?
|
Cytoskeleton | 2 | 2013 | 192 | 0.130 |
Why?
|
Bronchopulmonary Dysplasia | 2 | 2005 | 39 | 0.120 |
Why?
|
Physicians | 1 | 2022 | 672 | 0.120 |
Why?
|
Interferon Type I | 1 | 2015 | 175 | 0.120 |
Why?
|
Statistics, Nonparametric | 3 | 2009 | 307 | 0.120 |
Why?
|
Vasospasm, Intracranial | 2 | 2004 | 36 | 0.120 |
Why?
|
Family Health | 2 | 2011 | 162 | 0.120 |
Why?
|
Infant, Premature | 5 | 2010 | 287 | 0.120 |
Why?
|
CpG Islands | 2 | 2016 | 150 | 0.120 |
Why?
|
Tuberculosis | 1 | 2015 | 108 | 0.120 |
Why?
|
Pathology | 1 | 2013 | 30 | 0.120 |
Why?
|
Mice | 13 | 2023 | 11313 | 0.120 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2013 | 12 | 0.120 |
Why?
|
Computer-Assisted Instruction | 1 | 2013 | 43 | 0.120 |
Why?
|
Head and Neck Neoplasms | 3 | 2006 | 1051 | 0.120 |
Why?
|
Overweight | 2 | 2011 | 118 | 0.110 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2013 | 79 | 0.110 |
Why?
|
Neurosurgical Procedures | 2 | 2007 | 213 | 0.110 |
Why?
|
Quinazolines | 2 | 2005 | 220 | 0.110 |
Why?
|
Inhalation Exposure | 1 | 2013 | 28 | 0.110 |
Why?
|
Indians, North American | 1 | 2013 | 48 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2007 | 850 | 0.110 |
Why?
|
Vimentin | 1 | 2012 | 44 | 0.110 |
Why?
|
Hypersensitivity, Immediate | 1 | 2013 | 62 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 2 | 2018 | 3347 | 0.110 |
Why?
|
Reproductive Physiological Phenomena | 1 | 2012 | 4 | 0.110 |
Why?
|
Intestinal Mucosa | 1 | 2018 | 788 | 0.110 |
Why?
|
Immunity, Innate | 1 | 2016 | 405 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 2594 | 0.110 |
Why?
|
Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 10 | 0.110 |
Why?
|
Lung Diseases | 2 | 2013 | 263 | 0.110 |
Why?
|
Estrogen Receptor beta | 1 | 2012 | 25 | 0.110 |
Why?
|
Thyroid Neoplasms | 1 | 2017 | 406 | 0.110 |
Why?
|
Epigenomics | 1 | 2013 | 98 | 0.110 |
Why?
|
Lactation | 1 | 2012 | 53 | 0.110 |
Why?
|
Mesalamine | 2 | 2003 | 88 | 0.110 |
Why?
|
Waist-Hip Ratio | 1 | 2012 | 18 | 0.110 |
Why?
|
Remission Induction | 3 | 2012 | 722 | 0.110 |
Why?
|
Body Fat Distribution | 1 | 2012 | 13 | 0.110 |
Why?
|
Drug Administration Schedule | 4 | 2007 | 916 | 0.110 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 211 | 0.110 |
Why?
|
Allergens | 1 | 2013 | 179 | 0.100 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2013 | 173 | 0.100 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2016 | 199 | 0.100 |
Why?
|
Receptors, Androgen | 1 | 2012 | 110 | 0.100 |
Why?
|
Alcohol Drinking | 1 | 2014 | 264 | 0.100 |
Why?
|
Sex Distribution | 1 | 2012 | 173 | 0.100 |
Why?
|
E-Box Elements | 1 | 2011 | 5 | 0.100 |
Why?
|
Data Collection | 2 | 2023 | 371 | 0.100 |
Why?
|
Carrier Proteins | 1 | 2015 | 672 | 0.100 |
Why?
|
Survivors | 2 | 2015 | 225 | 0.100 |
Why?
|
Pregnatrienes | 3 | 2007 | 14 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2003 | 241 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2011 | 137 | 0.100 |
Why?
|
Behavior Therapy | 1 | 2011 | 75 | 0.100 |
Why?
|
Child Health Services | 1 | 2011 | 49 | 0.100 |
Why?
|
Sirolimus | 1 | 2012 | 169 | 0.100 |
Why?
|
DNA Copy Number Variations | 1 | 2011 | 171 | 0.100 |
Why?
|
Schools | 1 | 2011 | 66 | 0.090 |
Why?
|
Patient Compliance | 2 | 2015 | 226 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 826 | 0.090 |
Why?
|
Gene Fusion | 1 | 2010 | 38 | 0.090 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 378 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2005 | 508 | 0.090 |
Why?
|
Electroconvulsive Therapy | 1 | 2010 | 24 | 0.090 |
Why?
|
Infant, Premature, Diseases | 1 | 2010 | 78 | 0.090 |
Why?
|
RecQ Helicases | 1 | 2009 | 6 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2019 | 455 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2007 | 43 | 0.090 |
Why?
|
Vasodilator Agents | 1 | 2010 | 152 | 0.090 |
Why?
|
Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 12 | 0.090 |
Why?
|
Carcinosarcoma | 1 | 2010 | 20 | 0.090 |
Why?
|
Oxygen Consumption | 2 | 2007 | 239 | 0.090 |
Why?
|
Whole Genome Sequencing | 2 | 2021 | 76 | 0.090 |
Why?
|
Community Health Services | 1 | 2011 | 80 | 0.090 |
Why?
|
Inflammation | 2 | 2013 | 913 | 0.090 |
Why?
|
Senegal | 1 | 2009 | 4 | 0.090 |
Why?
|
Orchiectomy | 2 | 2007 | 67 | 0.090 |
Why?
|
Headache | 1 | 2010 | 73 | 0.090 |
Why?
|
MAP Kinase Kinase 6 | 2 | 2007 | 12 | 0.090 |
Why?
|
Neuroprotective Agents | 3 | 2007 | 94 | 0.090 |
Why?
|
Epigenesis, Genetic | 2 | 2016 | 476 | 0.090 |
Why?
|
Reading | 1 | 2009 | 30 | 0.090 |
Why?
|
Benzenesulfonates | 1 | 2010 | 66 | 0.090 |
Why?
|
Exons | 2 | 2010 | 450 | 0.090 |
Why?
|
Wnt Proteins | 1 | 2010 | 123 | 0.090 |
Why?
|
Quality Improvement | 1 | 2013 | 423 | 0.090 |
Why?
|
Gene Rearrangement | 1 | 2010 | 170 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 279 | 0.090 |
Why?
|
Patient Selection | 1 | 2013 | 685 | 0.090 |
Why?
|
Transcription Factors | 2 | 2009 | 1555 | 0.090 |
Why?
|
Cumulus Cells | 1 | 2008 | 7 | 0.090 |
Why?
|
Salvage Therapy | 2 | 2007 | 232 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 589 | 0.090 |
Why?
|
Gadolinium DTPA | 1 | 2010 | 261 | 0.090 |
Why?
|
alpha-Tocopherol | 1 | 2008 | 9 | 0.090 |
Why?
|
Health Promotion | 1 | 2011 | 160 | 0.090 |
Why?
|
DNA Replication | 1 | 2009 | 164 | 0.090 |
Why?
|
Ascorbic Acid | 1 | 2008 | 37 | 0.090 |
Why?
|
Rad51 Recombinase | 1 | 2009 | 80 | 0.090 |
Why?
|
Core Binding Factors | 1 | 2008 | 12 | 0.090 |
Why?
|
Attitude to Health | 2 | 2011 | 220 | 0.090 |
Why?
|
Ovariectomy | 1 | 2009 | 81 | 0.080 |
Why?
|
Animals | 14 | 2023 | 26518 | 0.080 |
Why?
|
Condoms | 1 | 2009 | 36 | 0.080 |
Why?
|
Depsipeptides | 1 | 2008 | 29 | 0.080 |
Why?
|
Unsafe Sex | 1 | 2009 | 42 | 0.080 |
Why?
|
Spinal Diseases | 1 | 2008 | 44 | 0.080 |
Why?
|
Coculture Techniques | 1 | 2008 | 164 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2016 | 458 | 0.080 |
Why?
|
Exome | 2 | 2019 | 127 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 5 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2008 | 85 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 24 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 138 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Protein 5 | 1 | 2008 | 7 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2008 | 111 | 0.080 |
Why?
|
Decision Making | 1 | 2014 | 641 | 0.080 |
Why?
|
GATA3 Transcription Factor | 2 | 2021 | 48 | 0.080 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 179 | 0.080 |
Why?
|
Sexual Partners | 1 | 2009 | 93 | 0.080 |
Why?
|
Genetic Carrier Screening | 1 | 2007 | 60 | 0.080 |
Why?
|
Oocytes | 1 | 2008 | 220 | 0.080 |
Why?
|
Spinal Fusion | 1 | 2008 | 85 | 0.080 |
Why?
|
Pyridines | 1 | 2010 | 309 | 0.080 |
Why?
|
Drug Discovery | 1 | 2008 | 103 | 0.080 |
Why?
|
MAP Kinase Signaling System | 2 | 2006 | 192 | 0.080 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2007 | 34 | 0.080 |
Why?
|
Genetic Markers | 1 | 2008 | 476 | 0.080 |
Why?
|
Infant, Newborn | 6 | 2010 | 2369 | 0.080 |
Why?
|
Fatty Liver | 1 | 2009 | 124 | 0.080 |
Why?
|
Cell Cycle Proteins | 2 | 2011 | 388 | 0.080 |
Why?
|
Pain | 1 | 2010 | 389 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 589 | 0.080 |
Why?
|
Spinal Osteophytosis | 1 | 2007 | 3 | 0.080 |
Why?
|
Sexually Transmitted Diseases | 1 | 2009 | 91 | 0.080 |
Why?
|
Urologic Neoplasms | 1 | 2008 | 77 | 0.080 |
Why?
|
Swine | 1 | 2008 | 554 | 0.080 |
Why?
|
Aneurysm, Ruptured | 1 | 2007 | 51 | 0.080 |
Why?
|
Transplantation, Homologous | 2 | 2012 | 996 | 0.080 |
Why?
|
Protein Processing, Post-Translational | 1 | 2009 | 371 | 0.080 |
Why?
|
Exercise Tolerance | 1 | 2007 | 48 | 0.080 |
Why?
|
Mouth Neoplasms | 1 | 2009 | 194 | 0.080 |
Why?
|
Macrophages | 1 | 2010 | 554 | 0.080 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2007 | 9 | 0.080 |
Why?
|
Bilirubin | 1 | 2007 | 124 | 0.070 |
Why?
|
Back Pain | 1 | 2007 | 42 | 0.070 |
Why?
|
Cerebral Hemorrhage | 2 | 2007 | 325 | 0.070 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 329 | 0.070 |
Why?
|
Spinal Stenosis | 1 | 2007 | 26 | 0.070 |
Why?
|
Child, Preschool | 6 | 2011 | 3608 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 206 | 0.070 |
Why?
|
Respiratory Sounds | 2 | 2017 | 33 | 0.070 |
Why?
|
Aminosalicylic Acids | 1 | 2006 | 42 | 0.070 |
Why?
|
Fetal Membranes, Premature Rupture | 1 | 2006 | 18 | 0.070 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2007 | 201 | 0.070 |
Why?
|
Walking | 1 | 2007 | 86 | 0.070 |
Why?
|
Infliximab | 1 | 2007 | 151 | 0.070 |
Why?
|
Mortality | 1 | 2007 | 148 | 0.070 |
Why?
|
Image Enhancement | 1 | 2010 | 563 | 0.070 |
Why?
|
Pilot Projects | 4 | 2014 | 837 | 0.070 |
Why?
|
Decompression, Surgical | 1 | 2007 | 87 | 0.070 |
Why?
|
Preoperative Care | 2 | 2006 | 390 | 0.070 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2007 | 51 | 0.070 |
Why?
|
Software | 3 | 2020 | 650 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2007 | 277 | 0.070 |
Why?
|
Exercise Test | 1 | 2007 | 164 | 0.070 |
Why?
|
Androgen Antagonists | 1 | 2007 | 140 | 0.070 |
Why?
|
Life Style | 1 | 2007 | 188 | 0.070 |
Why?
|
Intracranial Aneurysm | 1 | 2007 | 158 | 0.070 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 103 | 0.070 |
Why?
|
Obstetric Labor, Premature | 1 | 2006 | 58 | 0.070 |
Why?
|
Barbados | 2 | 2018 | 7 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2010 | 225 | 0.070 |
Why?
|
Databases, Genetic | 2 | 2018 | 259 | 0.070 |
Why?
|
Osteoporosis | 1 | 2007 | 121 | 0.070 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 145 | 0.070 |
Why?
|
MCF-7 Cells | 2 | 2016 | 106 | 0.070 |
Why?
|
S100 Proteins | 1 | 2005 | 50 | 0.070 |
Why?
|
Animal Identification Systems | 1 | 2005 | 3 | 0.070 |
Why?
|
Alloys | 1 | 2005 | 10 | 0.070 |
Why?
|
Data Display | 2 | 2020 | 24 | 0.070 |
Why?
|
ROC Curve | 2 | 2023 | 752 | 0.070 |
Why?
|
RNA, Small Interfering | 3 | 2015 | 547 | 0.070 |
Why?
|
Ear, External | 1 | 2005 | 26 | 0.070 |
Why?
|
Appointments and Schedules | 1 | 2005 | 53 | 0.070 |
Why?
|
Precancerous Conditions | 1 | 2006 | 196 | 0.070 |
Why?
|
Syringes | 1 | 2005 | 13 | 0.070 |
Why?
|
Contrast Media | 1 | 2010 | 1076 | 0.070 |
Why?
|
Complement C4b | 1 | 2005 | 35 | 0.060 |
Why?
|
Hepatitis C | 2 | 2005 | 208 | 0.060 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2006 | 164 | 0.060 |
Why?
|
Cladribine | 1 | 2004 | 35 | 0.060 |
Why?
|
Sex Factors | 3 | 2016 | 1053 | 0.060 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2007 | 217 | 0.060 |
Why?
|
Capillaries | 1 | 2005 | 91 | 0.060 |
Why?
|
Osteosarcoma | 1 | 2005 | 158 | 0.060 |
Why?
|
Disease-Free Survival | 4 | 2010 | 1203 | 0.060 |
Why?
|
Oncogene Proteins, Viral | 1 | 2004 | 34 | 0.060 |
Why?
|
Operating Rooms | 1 | 2005 | 126 | 0.060 |
Why?
|
Ambulatory Care | 1 | 2005 | 180 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2007 | 351 | 0.060 |
Why?
|
Area Under Curve | 2 | 2021 | 334 | 0.060 |
Why?
|
Mitral Valve Stenosis | 1 | 2003 | 37 | 0.060 |
Why?
|
Marital Status | 1 | 2023 | 40 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2021 | 2699 | 0.060 |
Why?
|
Biomarkers | 3 | 2018 | 1709 | 0.060 |
Why?
|
Hypertension, Pulmonary | 1 | 2007 | 345 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2007 | 878 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2005 | 460 | 0.060 |
Why?
|
Molecular Sequence Data | 3 | 2012 | 3029 | 0.060 |
Why?
|
Diet | 2 | 2019 | 442 | 0.060 |
Why?
|
Muscle Proteins | 1 | 2003 | 132 | 0.060 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2013 | 69 | 0.060 |
Why?
|
RNA Interference | 2 | 2016 | 368 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2003 | 60 | 0.050 |
Why?
|
Echocardiography, Doppler | 1 | 2003 | 187 | 0.050 |
Why?
|
Colonoscopy | 2 | 2018 | 260 | 0.050 |
Why?
|
Vinblastine | 1 | 2002 | 108 | 0.050 |
Why?
|
Leukomalacia, Periventricular | 3 | 2009 | 18 | 0.050 |
Why?
|
Cytokines | 1 | 2006 | 775 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2006 | 376 | 0.050 |
Why?
|
Administration, Inhalation | 3 | 2010 | 188 | 0.050 |
Why?
|
Extremities | 1 | 2003 | 165 | 0.050 |
Why?
|
Germ Cells | 1 | 2023 | 126 | 0.050 |
Why?
|
Pharmacists | 1 | 2022 | 32 | 0.050 |
Why?
|
Synaptophysin | 1 | 2021 | 11 | 0.050 |
Why?
|
Polymerase Chain Reaction | 3 | 2010 | 927 | 0.050 |
Why?
|
Neuropsychological Tests | 3 | 2009 | 502 | 0.050 |
Why?
|
Neoplasm, Residual | 1 | 2023 | 162 | 0.050 |
Why?
|
Mitral Valve | 1 | 2003 | 247 | 0.050 |
Why?
|
Recurrence | 3 | 2012 | 1137 | 0.050 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 62 | 0.050 |
Why?
|
Regression Analysis | 2 | 2017 | 595 | 0.050 |
Why?
|
Aromatase Inhibitors | 1 | 2021 | 28 | 0.050 |
Why?
|
Sarcoma | 1 | 2003 | 211 | 0.050 |
Why?
|
Suburban Population | 1 | 2001 | 6 | 0.050 |
Why?
|
Family | 2 | 2018 | 311 | 0.050 |
Why?
|
Mice, Transgenic | 4 | 2007 | 1537 | 0.050 |
Why?
|
Cell Survival | 2 | 2015 | 966 | 0.050 |
Why?
|
Trastuzumab | 1 | 2021 | 68 | 0.050 |
Why?
|
Data Accuracy | 1 | 2021 | 31 | 0.050 |
Why?
|
Disease Progression | 3 | 2012 | 1531 | 0.050 |
Why?
|
Taxoids | 1 | 2021 | 129 | 0.050 |
Why?
|
Needs Assessment | 1 | 2022 | 154 | 0.050 |
Why?
|
Repressor Proteins | 1 | 2004 | 403 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2004 | 329 | 0.050 |
Why?
|
DNA, Neoplasm | 2 | 2012 | 265 | 0.050 |
Why?
|
Protein Binding | 3 | 2009 | 1454 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
Aging | 1 | 2005 | 689 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2005 | 541 | 0.050 |
Why?
|
Feasibility Studies | 3 | 2011 | 751 | 0.050 |
Why?
|
Europe | 1 | 2021 | 308 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2012 | 1958 | 0.050 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 1 | 2019 | 16 | 0.050 |
Why?
|
Fanconi Anemia | 1 | 2019 | 7 | 0.050 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 53 | 0.040 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2006 | 546 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 877 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2003 | 425 | 0.040 |
Why?
|
Health Behavior | 2 | 2011 | 183 | 0.040 |
Why?
|
Menopause | 1 | 2019 | 71 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 98 | 0.040 |
Why?
|
Haploinsufficiency | 1 | 2019 | 62 | 0.040 |
Why?
|
APOBEC Deaminases | 1 | 2018 | 5 | 0.040 |
Why?
|
Graft Rejection | 1 | 2005 | 1064 | 0.040 |
Why?
|
Palpation | 1 | 2018 | 18 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2018 | 70 | 0.040 |
Why?
|
Pregnancy Trimester, Third | 1 | 2018 | 70 | 0.040 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2003 | 516 | 0.040 |
Why?
|
Research Personnel | 1 | 2019 | 67 | 0.040 |
Why?
|
RNA, Messenger | 3 | 2011 | 1975 | 0.040 |
Why?
|
Cholesterol, LDL | 1 | 2019 | 222 | 0.040 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 415 | 0.040 |
Why?
|
Image-Guided Biopsy | 1 | 2018 | 65 | 0.040 |
Why?
|
Penetrance | 1 | 2018 | 44 | 0.040 |
Why?
|
Kidney Transplantation | 1 | 2005 | 846 | 0.040 |
Why?
|
Ultrasonography, Mammary | 1 | 2018 | 82 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2003 | 620 | 0.040 |
Why?
|
Self Report | 1 | 2019 | 287 | 0.040 |
Why?
|
Cadherins | 1 | 2018 | 151 | 0.040 |
Why?
|
Observer Variation | 2 | 2013 | 601 | 0.040 |
Why?
|
Mothers | 1 | 2018 | 140 | 0.040 |
Why?
|
Acute Disease | 2 | 2012 | 824 | 0.040 |
Why?
|
Physical Examination | 1 | 2018 | 149 | 0.040 |
Why?
|
Cells, Cultured | 2 | 2016 | 2810 | 0.040 |
Why?
|
Brain | 1 | 2007 | 2211 | 0.040 |
Why?
|
Reproduction | 1 | 2018 | 195 | 0.040 |
Why?
|
Geography | 1 | 2018 | 223 | 0.040 |
Why?
|
Biomass | 1 | 2017 | 32 | 0.040 |
Why?
|
MAP Kinase Kinase 7 | 2 | 2007 | 21 | 0.040 |
Why?
|
Gene Expression | 2 | 2016 | 1281 | 0.040 |
Why?
|
High Mobility Group Proteins | 1 | 2016 | 26 | 0.040 |
Why?
|
Cell Proliferation | 2 | 2015 | 1571 | 0.040 |
Why?
|
Genetics, Population | 2 | 2011 | 394 | 0.040 |
Why?
|
Liver | 2 | 2013 | 1229 | 0.040 |
Why?
|
Antigens, CD | 1 | 2018 | 457 | 0.040 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 27 | 0.040 |
Why?
|
Morbidity | 1 | 2017 | 146 | 0.040 |
Why?
|
Interferon Regulatory Factor-3 | 1 | 2016 | 13 | 0.040 |
Why?
|
Chemokine CCL5 | 1 | 2016 | 16 | 0.040 |
Why?
|
Poly I-C | 1 | 2016 | 16 | 0.040 |
Why?
|
Serum Response Factor | 1 | 2016 | 44 | 0.040 |
Why?
|
Cough | 1 | 2016 | 53 | 0.040 |
Why?
|
Chemokine CXCL10 | 1 | 2016 | 17 | 0.040 |
Why?
|
Thyroidectomy | 1 | 2017 | 170 | 0.040 |
Why?
|
Endosomes | 1 | 2016 | 75 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2008 | 418 | 0.030 |
Why?
|
Lysosomes | 1 | 2016 | 104 | 0.030 |
Why?
|
Carcinogenesis | 1 | 2017 | 194 | 0.030 |
Why?
|
Selection Bias | 1 | 2015 | 37 | 0.030 |
Why?
|
Ethambutol | 1 | 2015 | 6 | 0.030 |
Why?
|
Pyrazinamide | 1 | 2015 | 5 | 0.030 |
Why?
|
Isoniazid | 1 | 2015 | 8 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2016 | 268 | 0.030 |
Why?
|
Autophagy-Related Proteins | 1 | 2015 | 20 | 0.030 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2015 | 12 | 0.030 |
Why?
|
Rifampin | 1 | 2015 | 22 | 0.030 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 191 | 0.030 |
Why?
|
Colitis | 1 | 2018 | 236 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2016 | 143 | 0.030 |
Why?
|
Hepatitis C, Chronic | 1 | 2016 | 126 | 0.030 |
Why?
|
Nucleotides | 1 | 2015 | 95 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2017 | 377 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2015 | 319 | 0.030 |
Why?
|
Algorithms | 2 | 2014 | 1828 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2014 | 128 | 0.030 |
Why?
|
Phenotype | 2 | 2014 | 2375 | 0.030 |
Why?
|
Fourier Analysis | 1 | 2014 | 125 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2016 | 230 | 0.030 |
Why?
|
Cell Line | 2 | 2009 | 2466 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 1073 | 0.030 |
Why?
|
Allelic Imbalance | 1 | 2013 | 20 | 0.030 |
Why?
|
Histocytochemistry | 1 | 2013 | 130 | 0.030 |
Why?
|
Laboratories | 1 | 2013 | 43 | 0.030 |
Why?
|
Blood Pressure | 2 | 2011 | 1143 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 124 | 0.030 |
Why?
|
Transcription, Genetic | 2 | 2009 | 1135 | 0.030 |
Why?
|
Skin Tests | 1 | 2013 | 44 | 0.030 |
Why?
|
Computer Simulation | 1 | 2018 | 1077 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2003 | 2183 | 0.030 |
Why?
|
Multigene Family | 1 | 2014 | 202 | 0.030 |
Why?
|
Suppression, Genetic | 1 | 2013 | 30 | 0.030 |
Why?
|
Axilla | 1 | 2013 | 97 | 0.030 |
Why?
|
Dust | 1 | 2013 | 26 | 0.030 |
Why?
|
Cell Cycle | 1 | 2015 | 502 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 136 | 0.030 |
Why?
|
Oxidants | 1 | 2013 | 86 | 0.030 |
Why?
|
Nutritional Status | 1 | 2013 | 83 | 0.030 |
Why?
|
Environmental Monitoring | 1 | 2013 | 71 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2014 | 202 | 0.030 |
Why?
|
Immunoglobulin E | 1 | 2013 | 143 | 0.030 |
Why?
|
Tanzania | 1 | 2012 | 45 | 0.030 |
Why?
|
Models, Genetic | 1 | 2018 | 926 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2005 | 1040 | 0.030 |
Why?
|
Cytoplasm | 1 | 2013 | 281 | 0.030 |
Why?
|
Waist Circumference | 1 | 2012 | 20 | 0.030 |
Why?
|
Doxorubicin | 1 | 2013 | 289 | 0.030 |
Why?
|
Mitoxantrone | 1 | 2012 | 68 | 0.030 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2011 | 13 | 0.030 |
Why?
|
Quality Assurance, Health Care | 1 | 2013 | 220 | 0.030 |
Why?
|
Air Pollutants | 1 | 2013 | 78 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2012 | 79 | 0.030 |
Why?
|
Fanconi Anemia Complementation Group N Protein | 1 | 2011 | 13 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2011 | 40 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 272 | 0.030 |
Why?
|
Advisory Committees | 1 | 2012 | 90 | 0.030 |
Why?
|
Mutation Rate | 1 | 2012 | 48 | 0.030 |
Why?
|
Antioxidants | 1 | 2013 | 223 | 0.030 |
Why?
|
Chronic Disease | 2 | 2006 | 968 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2011 | 52 | 0.030 |
Why?
|
DNA, Recombinant | 1 | 2011 | 67 | 0.030 |
Why?
|
Codon, Nonsense | 1 | 2011 | 41 | 0.030 |
Why?
|
Consensus Sequence | 1 | 2011 | 64 | 0.030 |
Why?
|
HapMap Project | 1 | 2011 | 47 | 0.030 |
Why?
|
Cytarabine | 1 | 2012 | 218 | 0.030 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2012 | 121 | 0.030 |
Why?
|
Genes, myc | 1 | 2011 | 39 | 0.030 |
Why?
|
Feces | 1 | 2013 | 316 | 0.020 |
Why?
|
Internet | 1 | 2013 | 309 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2015 | 388 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 181 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2013 | 579 | 0.020 |
Why?
|
Ataxin-7 | 1 | 2010 | 5 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 153 | 0.020 |
Why?
|
Community-Based Participatory Research | 1 | 2011 | 36 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2011 | 266 | 0.020 |
Why?
|
Chromosome Breakpoints | 1 | 2010 | 15 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2012 | 183 | 0.020 |
Why?
|
Sentinel Surveillance | 1 | 2010 | 23 | 0.020 |
Why?
|
Heredity | 1 | 2010 | 19 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2011 | 269 | 0.020 |
Why?
|
Models, Biological | 2 | 2008 | 1748 | 0.020 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2011 | 148 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
Cholangitis, Sclerosing | 1 | 2010 | 52 | 0.020 |
Why?
|
Mental Status Schedule | 1 | 2009 | 25 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2013 | 446 | 0.020 |
Why?
|
Smoking | 1 | 2014 | 605 | 0.020 |
Why?
|
Niacinamide | 1 | 2010 | 116 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2010 | 151 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2010 | 113 | 0.020 |
Why?
|
Transfection | 1 | 2011 | 895 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2009 | 188 | 0.020 |
Why?
|
Social Class | 1 | 2009 | 127 | 0.020 |
Why?
|
Parthenogenesis | 1 | 2008 | 3 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2009 | 49 | 0.020 |
Why?
|
Cleavage Stage, Ovum | 1 | 2008 | 6 | 0.020 |
Why?
|
Colectomy | 1 | 2010 | 166 | 0.020 |
Why?
|
Social Support | 1 | 2011 | 193 | 0.020 |
Why?
|
Blastocyst | 1 | 2008 | 33 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2007 | 3087 | 0.020 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 55 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2009 | 133 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2009 | 73 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2009 | 73 | 0.020 |
Why?
|
Apoptosis | 2 | 2008 | 1678 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2008 | 141 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2009 | 270 | 0.020 |
Why?
|
Azacitidine | 1 | 2009 | 137 | 0.020 |
Why?
|
Binding Sites | 1 | 2011 | 1098 | 0.020 |
Why?
|
Hemagglutinins | 1 | 2008 | 19 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2008 | 63 | 0.020 |
Why?
|
Triglycerides | 1 | 2009 | 232 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2008 | 83 | 0.020 |
Why?
|
Hemoglobinometry | 1 | 2007 | 9 | 0.020 |
Why?
|
Oxyhemoglobins | 1 | 2007 | 31 | 0.020 |
Why?
|
Founder Effect | 1 | 2008 | 104 | 0.020 |
Why?
|
Lupus Nephritis | 1 | 2009 | 78 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2008 | 136 | 0.020 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2008 | 85 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2010 | 427 | 0.020 |
Why?
|
Omentum | 1 | 2008 | 71 | 0.020 |
Why?
|
MAP Kinase Kinase Kinase 4 | 1 | 2007 | 4 | 0.020 |
Why?
|
Glasgow Outcome Scale | 1 | 2007 | 7 | 0.020 |
Why?
|
Students | 1 | 2009 | 146 | 0.020 |
Why?
|
DNA Damage | 1 | 2009 | 362 | 0.020 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2007 | 21 | 0.020 |
Why?
|
Transgenes | 1 | 2008 | 180 | 0.020 |
Why?
|
Alemtuzumab | 1 | 2007 | 83 | 0.020 |
Why?
|
Dinucleotide Repeats | 1 | 2007 | 13 | 0.020 |
Why?
|
Bone Remodeling | 1 | 2007 | 24 | 0.020 |
Why?
|
Hypoxia, Brain | 1 | 2007 | 41 | 0.020 |
Why?
|
Exercise | 1 | 2011 | 315 | 0.020 |
Why?
|
Melphalan | 1 | 2007 | 97 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2007 | 84 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2007 | 60 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2010 | 503 | 0.020 |
Why?
|
Polysomnography | 1 | 2007 | 150 | 0.020 |
Why?
|
Jamaica | 1 | 2007 | 5 | 0.020 |
Why?
|
Radiography | 1 | 2009 | 812 | 0.020 |
Why?
|
Hemoglobins | 1 | 2007 | 179 | 0.020 |
Why?
|
Vidarabine | 1 | 2007 | 141 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2007 | 303 | 0.020 |
Why?
|
Pain Measurement | 1 | 2008 | 321 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 113 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2011 | 502 | 0.020 |
Why?
|
Cardiac Output | 1 | 2007 | 156 | 0.020 |
Why?
|
Sulfasalazine | 1 | 2006 | 34 | 0.020 |
Why?
|
Cholesterol | 1 | 2009 | 356 | 0.020 |
Why?
|
Reference Values | 1 | 2007 | 673 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2006 | 66 | 0.020 |
Why?
|
Fatty Acids | 1 | 2007 | 129 | 0.020 |
Why?
|
Mice, Nude | 1 | 2008 | 790 | 0.020 |
Why?
|
Dietary Fats | 1 | 2007 | 134 | 0.020 |
Why?
|
S100 Calcium Binding Protein A6 | 1 | 2005 | 12 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 104 | 0.020 |
Why?
|
Uncertainty | 1 | 2006 | 71 | 0.020 |
Why?
|
Transforming Growth Factor alpha | 1 | 2005 | 50 | 0.020 |
Why?
|
Neck Dissection | 1 | 2006 | 65 | 0.020 |
Why?
|
Hearing Loss, Bilateral | 1 | 2005 | 9 | 0.020 |
Why?
|
Nickel | 1 | 2005 | 13 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2006 | 105 | 0.020 |
Why?
|
DNA Primers | 1 | 2006 | 542 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 632 | 0.020 |
Why?
|
Gestational Age | 1 | 2006 | 310 | 0.020 |
Why?
|
Mice, SCID | 1 | 2006 | 252 | 0.020 |
Why?
|
Blindness | 1 | 2005 | 41 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2006 | 391 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2007 | 271 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 2007 | 373 | 0.020 |
Why?
|
Copper | 1 | 2005 | 71 | 0.020 |
Why?
|
Anxiety | 1 | 2007 | 287 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2005 | 305 | 0.020 |
Why?
|
Probability | 1 | 2006 | 355 | 0.020 |
Why?
|
Patient Admission | 1 | 2005 | 112 | 0.020 |
Why?
|
Cerebral Palsy | 1 | 2005 | 90 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2004 | 56 | 0.020 |
Why?
|
Ethylnitrosourea | 1 | 2004 | 30 | 0.020 |
Why?
|
Educational Status | 1 | 2005 | 187 | 0.020 |
Why?
|
Phosphorylation | 1 | 2007 | 1101 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2006 | 363 | 0.020 |
Why?
|
Oncogenes | 1 | 2004 | 88 | 0.020 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2004 | 31 | 0.020 |
Why?
|
Intellectual Disability | 1 | 2005 | 185 | 0.020 |
Why?
|
Cisplatin | 1 | 2006 | 612 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2007 | 313 | 0.020 |
Why?
|
Nimodipine | 1 | 2003 | 11 | 0.020 |
Why?
|
Cerebral Angiography | 1 | 2004 | 196 | 0.020 |
Why?
|
Prostatectomy | 1 | 2007 | 457 | 0.010 |
Why?
|
Desmin | 1 | 2003 | 10 | 0.010 |
Why?
|
Neutropenia | 1 | 2004 | 215 | 0.010 |
Why?
|
Infant, Low Birth Weight | 1 | 2003 | 58 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 407 | 0.010 |
Why?
|
Myoglobin | 1 | 2003 | 29 | 0.010 |
Why?
|
Fatigue | 1 | 2004 | 174 | 0.010 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2003 | 60 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 68 | 0.010 |
Why?
|
Communicable Disease Control | 1 | 2003 | 51 | 0.010 |
Why?
|
Intubation, Gastrointestinal | 1 | 2003 | 31 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2004 | 183 | 0.010 |
Why?
|
Sample Size | 1 | 2003 | 130 | 0.010 |
Why?
|
Cytogenetic Analysis | 1 | 2003 | 71 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2004 | 509 | 0.010 |
Why?
|
Random Allocation | 1 | 2003 | 332 | 0.010 |
Why?
|
Survival | 1 | 2002 | 21 | 0.010 |
Why?
|
Intracranial Hemorrhages | 1 | 2003 | 119 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2003 | 222 | 0.010 |
Why?
|
Infant | 1 | 2009 | 3036 | 0.010 |
Why?
|
Cell Movement | 1 | 2005 | 756 | 0.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2007 | 929 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2003 | 328 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 429 | 0.010 |
Why?
|
Fluorouracil | 1 | 2003 | 556 | 0.010 |
Why?
|
Illinois | 1 | 2003 | 461 | 0.010 |
Why?
|
Carboplatin | 1 | 2002 | 286 | 0.010 |
Why?
|
Administration, Oral | 1 | 2003 | 683 | 0.010 |
Why?
|
Hepatitis C Antibodies | 1 | 2001 | 8 | 0.010 |
Why?
|
HIV Antibodies | 1 | 2001 | 25 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2002 | 692 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 893 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 696 | 0.010 |
Why?
|
Down-Regulation | 1 | 2002 | 504 | 0.010 |
Why?
|
Respiration, Artificial | 1 | 2003 | 332 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2007 | 2227 | 0.010 |
Why?
|
Actins | 1 | 2003 | 448 | 0.010 |
Why?
|
HIV-1 | 1 | 2001 | 163 | 0.010 |
Why?
|
ErbB Receptors | 1 | 2003 | 485 | 0.010 |
Why?
|
Hospitalization | 1 | 2004 | 844 | 0.010 |
Why?
|
Hypertension | 1 | 2003 | 1139 | 0.010 |
Why?
|